Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

Calabresi, Peter A.; Kieseier, Bernd C.; Arnold, Douglas L.; Balcer, Laura J.; Boyko, A. N.; Pelletier, Jean; Liu, Shifang; Zhu, Ying; Seddighzadeh, Ali; Hung, Serena; Deykin, Aaron

doi:10.1016/s1474-4422(14)70068-7

Cited by 354 publications

(460 citation statements)

References 28 publications

Supporting

Mentioning

408

Contrasting

Unclassified

Order By: Relevance

“…Studies on MS disease activity, such as clinical drug trials, indicate that the number of new MRI lesions is approximately 4–12 times larger than the number of new clinical relapses during the same time period 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20. Such “clinically silent” MRI lesions stress the importance of monitoring patients with MRI even in the absence of clinical signs of disease activity.…”

Section: Resultsmentioning

confidence: 99%

“…While we acknowledge this and would like to emphasize that the MRI frequency and timing should be adapted to the clinical situation, it is our opinion that general recommendations of MRI frequency are still valuable in the clinical care of patients. The recommendations regarding MRI frequency presented here are based on clinical experience and extrapolation of study data on the level of disease activity seen in treated and untreated patients with MS in phase III studies 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

et al. 2016

View full text Add to dashboard Cite

Multiple sclerosis (MS) is associated with inflammatory lesions in the brain and spinal cord. The detection of such inflammatory lesions using magnetic resonance imaging (MRI) is important in the consideration of the diagnosis and differential diagnoses of MS, as well as in the monitoring of disease activity and predicting treatment efficacy. Although there is strong evidence supporting the use of MRI for both the diagnosis and monitoring of disease activity, there is a lack of evidence regarding which MRI protocols to use, the frequency of examinations, and in what clinical situations to consider MRI examination. A national workshop to discuss these issues was held in Stockholm, Sweden, in August 2015, which resulted in a Swedish consensus statement regarding the use of MRI in the care of individuals with MS. The aim of this consensus statement is to provide practical advice for the use of MRI in this setting. The recommendations are based on a review of relevant literature and the clinical experience of workshop attendees. It is our hope that these recommendations will benefit individuals with MS and guide healthcare professionals responsible for their care.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The methods and results of the ADVANCE study have previously been published. 9 Briefly, patients aged 18 to 65 years with an Expanded Disability Status Scale score between 0.0 and 5.0 and a confirmed diagnosis of relapsing-remitting MS, as defined by the McDonald criteria, 14,15 were included in the study. Patients were randomized to receive peginterferon beta1a 125 μg subcutaneously every 2 or 4 weeks or placebo at 183 sites worldwide.…”

Section: Methodsmentioning

confidence: 99%

“…From the 183 sites that participated in ADVANCE, 84 investigators met the inclusion criteria and were invited to participate. Of 50 ADVANCE investigators who agreed to participate, 30 (ie, responders) completed questionnaire 1 and 29 also completed questionnaire 2 was evaluated during the 2-year, double-blind, randomized, placebo-controlled (year 1 only) ADVANCE study in patients with relapsing-remitting MS. 9 Results from year 1 demonstrated that the use of peginterferon beta1a 125 μg subcutaneously every 2 or 4 weeks significantly reduced the relapse rate, risk of relapse, disability progression, and number of magnetic resonance imaging brain lesions compared with placebo. 9 The most common adverse events in ADVANCE were FLSs and ISRs.…”

Section: Responder Demographicsmentioning

confidence: 99%

Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a

Halper

Centonze

Newsome

et al. 2016

International Journal of MS Care

View full text Add to dashboard Cite

A dherence to multiple sclerosis (MS) diseasemodifying therapies, such as interferons, has been linked to improved treatment outcomes and reduced health-care costs. 1,2 Reasons for poor patient adherence to prescribed MS therapies include frequency of administration and adverse events, such as flu-like symptoms (FLSs) and injection-site reactions (ISRs), associated with interferon beta treatments. [3][4][5][6][7][8] Peginterferon beta-1a is a pegylated form of interferon beta-1a approved for the treatment of relapsing forms of MS. The safety and efficacy of peginterferon beta-1a 125 μg administered subcutaneously every 2 or 4 weeks

show abstract

“…Several similar preparations have been marketed since, namely intramuscular IFN1βa (Avonex: Biogen, Cambridge, MA) [4], subcutaneous IFN-1βa (Rebif: Merck, Darmstadt, Germany) [5], and, more recently, pegylated IFN-1βa (pegIFN-1βa; Plegridy: Biogen, Cambridge, MA) [6]. They differ mainly in terms of application route and frequency (s.c. vs i.m.…”

Section: Ifn-βmentioning

confidence: 99%

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

2016

View full text Add to dashboard Cite

Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of diseasemodifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.

show abstract

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

Cited by 354 publications

References 28 publications

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

Contact Info

Product

Resources

About